Document is current
Any future updates will be listed below
-
Authors
Cassandras, Monica https://orcid.org/0000-0003-2379-503X
Sanchez, Xavier https://orcid.org/0000-0003-0897-0661
Hsu, Lauren https://orcid.org/0000-0002-6035-7381
Huang, Yu
Getzler, Adam J. https://orcid.org/0000-0001-8091-3851
Ganguly, Debolina
Baldominos, Pilar https://orcid.org/0000-0002-4988-6290
Codinachs, Ia
Chuong, Jeffrey https://orcid.org/0009-0009-9382-2145
Martin, Elizabeth E.
Smith, Blake E. https://orcid.org/0000-0001-9878-8198
Marina, Eleonora https://orcid.org/0009-0009-1892-1733
Spasic, Milos
Qin, Xingping https://orcid.org/0000-0003-3263-0843
Parsons, Heather A. https://orcid.org/0000-0001-8178-6612
Mayer, Erica L.
Sarosiek, Kristopher A. https://orcid.org/0000-0002-4618-5085
Dougan, Stephanie K. https://orcid.org/0000-0002-2263-363X
Mittendorf, Elizabeth A.
McAllister, Sandra S. https://orcid.org/0000-0002-5111-5903
Hsu, Ya-Chieh https://orcid.org/0000-0002-0178-7373
Agudo, Judith https://orcid.org/0000-0002-3576-3169
- License Information
-
More Information
Article History
Received: 21 November 2024
Accepted: 2 February 2026
First Online: 4 March 2026
Competing interests
: H.A.P. receives funding from Pfizer and Merck; and is the recipient of honoraria or consultation fees from Daiichi-Sankyo, AZ, Caris, SAGA, Natera, Illumina, Guardant, Sermonix and Lilly. E.L.M. is the recipient of honoraria or consultation fees from Lilly, AstraZeneca, Novartis and Arvinas. S.K.D. received research funding from Novartis, BMS, and Takeda unrelated to the current project and consulting fees from Revolution Medicines. The other authors declare no competing interests.
